← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
SNUH dexamethasone/ICG intratympanic delivery-vehicle study
Also known as: Dexamethasone saline ICG, Dexamethasone hyaluronic acid ICG, NCT06437054
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Drug Delivery
Stage
Phase 1/2
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
72%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
South Korea
Population
adult, sudden, sensorineural, drug-delivery, study-level
Trial IDs
1
Mechanism
Withdrawn randomized Phase 1/2 pilot comparing intratympanic dexamethasone plus saline plus indocyanine green with dexamethasone plus hyaluronic acid plus indocyanine green for intractable hearing loss.
Indications
Notes
Split out from the broad dexamethasone cluster. The registry verifies a withdrawn Seoul National University Hospital pilot of mixed intratympanic delivery vehicles; it should not be shown as a standalone dexamethasone product.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT06437054
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-verified-studydiscontinued-registry-studygeneric-drug-studydrug-delivery-studystudy-level-not-standalone-productnot-commercial-pipeline-program
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2